Monoclonal Antibodies for the Treatment of Acute Lymphocytic Leukemia: A Literature Review

Monoclonal Antibodies for the Treatment of Acute Lymphocytic Leukemia: A Literature Review Publisher Pubmed

Pourmontaseri H^{1, 2} ; Habibzadeh N³ ; Entezari S⁴ ; Samadian F⁵ ; Kiyani S⁶ ; Taheri M⁷ ; Ahmadi A⁸ ; Fallahi MS⁹ ; Sheikhzadeh F¹⁰ ; Ansari A¹¹ ; Tamimi A¹² ; Deravi N¹³

Show Affiliations

1. Student Research Committee, Fasa University of Medical Sciences, Fasa, Iran
2. Bitab Knowledge Enterprise, Fasa University of Medical Sciences, Fasa, Iran
3. Student Research Committee, School of Medical Sciences, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
4. Student Research Committee, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5. Nursing Department, Shahid Beheshti University of Medical Science, Tehran, Iran
6. Midwifery Department, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
7. Student Research Committee, School of Pharmacy Sciences, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
8. Faculty of Biological Sciences and Technologies, Islamic Azad University Sari Branch, Sari, Iran
9. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
10. Student Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
11. Student Research Committee, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran
12. Student Research Committee, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
13. Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: Human Antibodies Published:2022

Abstract

BACKGROUND: Acute lymphocytic leukemia (ALL) is a type of blood cancer that is more prevalent in children. Several treatment methods are available for ALL, including chemotherapy, upfront treatment regimens, and pediatric-inspired regimens for adults. Monoclonal antibodies (Mabs) are the novel Food and Drug Administration (FDA) approved remedies for the relapsed/refractory (R/R) adult ALL. In this article, we aimed to review studies that investigated the efficacy and safety of Mabs on ALL. METHODS: We gathered studies through a complete search with all proper related keywords in ISI Web of Science, SID, Scopus, Google Scholar, Science Direct, and PubMed for English language publications up to 2020. RESULTS: The most commonly studied Mabs for ALL therapies are CD-19, CD-20, CD-22, and CD-52. The best results have been reported in the administration of blinatumomab, rituximab, ofatumumab, and inotuzumab with acceptable low side effects. CONCLUSION: Appling personalized approach for achieving higher efficacy is one of the most important aspects of treatment. Moreover, we recommend that the wide use of these Mabs depends on designing further cost-effectiveness trials in this field. © 2022 - IOS Press. All rights reserved.

Related Docs

View other Related Docs

1. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)

2. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)

3. Anti-Cd20 Antibody Treatment for B-Cell Malignancies, Resistance to Anti-CD20 Antibodies and approaches for their Reversal: Volume 2 (2023)

4. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)

5. Cancer Immunology, Encyclopedia of Infection and Immunity (2022)

6. The Promising Role of Monoclonal Antibodies for Immunotherapy of the Hiv-Associated Cancer, Non-Hodgkin Lymphoma, International Reviews of Immunology (2018)

7. Tumor Immunology, Clinical Immunology (2022)

8. Exploring Cd19-Targeted Immunotherapy Strategies for Human B-Cell Lymphoma, Archives of Razi Institute (2025)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (6)

Saeid Amanpour (1)

Style	Citing Format
MLA	Pourmontaseri H, et al.. "Monoclonal Antibodies for the Treatment of Acute Lymphocytic Leukemia: A Literature Review." Human Antibodies, vol. 30, no. 3, 2022, pp. 117-130.
APA	Pourmontaseri H, Habibzadeh N, Entezari S, Samadian F, Kiyani S, Taheri M, Ahmadi A, Fallahi MS, Sheikhzadeh F, Ansari A, Tamimi A, Deravi N (2022). Monoclonal Antibodies for the Treatment of Acute Lymphocytic Leukemia: A Literature Review. Human Antibodies, 30(3), 117-130.
Chicago	Pourmontaseri H, Habibzadeh N, Entezari S, Samadian F, Kiyani S, Taheri M, Ahmadi A, et al.. "Monoclonal Antibodies for the Treatment of Acute Lymphocytic Leukemia: A Literature Review." Human Antibodies 30, no. 3 (2022): 117-130.
Harvard	Pourmontaseri H et al. (2022) 'Monoclonal Antibodies for the Treatment of Acute Lymphocytic Leukemia: A Literature Review', Human Antibodies, 30(3), pp. 117-130.
Vancouver	Pourmontaseri H, Habibzadeh N, Entezari S, Samadian F, Kiyani S, Taheri M, et al.. Monoclonal Antibodies for the Treatment of Acute Lymphocytic Leukemia: A Literature Review. Human Antibodies. 2022;30(3):117-130.
BibTex	@article{ author = {Pourmontaseri H and Habibzadeh N and Entezari S and Samadian F and Kiyani S and Taheri M and Ahmadi A and Fallahi MS and Sheikhzadeh F and Ansari A and Tamimi A and Deravi N}, title = {Monoclonal Antibodies for the Treatment of Acute Lymphocytic Leukemia: A Literature Review}, journal = {Human Antibodies}, volume = {30}, number = {3}, pages = {117-130}, year = {2022} }
RIS	TY - JOUR AU - Pourmontaseri H AU - Habibzadeh N AU - Entezari S AU - Samadian F AU - Kiyani S AU - Taheri M AU - Ahmadi A AU - Fallahi MS AU - Sheikhzadeh F AU - Ansari A AU - Tamimi A AU - Deravi N TI - Monoclonal Antibodies for the Treatment of Acute Lymphocytic Leukemia: A Literature Review JO - Human Antibodies VL - 30 IS - 3 SP - 117 EP - 130 PY - 2022 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract